All In Biotech

Drug Trial Radar · NCT00002755

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

PROSPECTIVE RANDOMISED EVALUATION OF HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR SUPPORT IN PATIENTS WITH HIGH RISK BREAST CANCER

Last checked: Nov 19, 2026Latest source record: Nov 6, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

600

Planned (sponsor's estimate)

Start

Nov 1995

Primary completion

Not stated

Study completion Jun 1999

Sponsor

Lead sponsor
Scottish Cancer Therapy NetworkAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which treatment regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of standard cyclophosphamide, methotrexate, and fluorouracil with that of high-dose combination chemotherapy plus peripheral stem cell transplantation in treating women who have stage II or stage IIIA breast cancer.

Conditions

  • Breast Cancer

Interventions

  • filgrastimBiological

  • CMF regimenDrug

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • fluorouracilDrug

  • methotrexateDrug

  • tamoxifen citrateDrug

  • thiotepaDrug

  • autologous bone marrow transplantationProcedure

  • peripheral blood stem cell transplantationProcedure

  • low-LET cobalt-60 gamma ray therapyRadiation

  • low-LET electron therapyRadiation

  • low-LET photon therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • St. Vincent's Hospital

    Dublin, Ireland

  • Addenbrooke's NHS Trust

    Cambridge, England, United Kingdom

  • Cheltenham General Hospital

    Cheltenham, England, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, England, United Kingdom

  • Royal Free Hospital

    Hampstead, London, England, United Kingdom

  • Northwick Park Hospital

    Harrow, England, United Kingdom

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom

  • St. James's Hospital

    Leeds, England, United Kingdom

  • St. George's Hospital

    London, England, United Kingdom

  • Middlesex Hospital- Meyerstein Institute

    London, England, United Kingdom

  • Newcastle General Hospital

    Newcastle upon Tyne, England, United Kingdom

  • Nottingham City Hospital NHS Trust

    Nottingham, England, United Kingdom

  • Derriford Hospital

    Plymouth, England, United Kingdom

  • Weston Park Hospital

    Sheffield, England, United Kingdom

  • Royal South Hants Hospital

    Southampton, England, United Kingdom

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, United Kingdom

  • Royal Infirmary

    Edinburgh, Scotland, United Kingdom

  • Western General Hospital

    Edinburgh, Scotland, United Kingdom

  • Beatson Oncology Centre

    Glasgow, Scotland, United Kingdom

  • Royal Infirmary

    Glasgow, Scotland, United Kingdom

  • Velindre Hospital

    Cardiff, Wales, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.